{"id":"thalidomide-prednisone-velcade","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neuropathy"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Thalidomide's antiangiogenic properties are thought to be responsible for its therapeutic effects. Prednisone's anti-inflammatory effects are mediated through its ability to suppress the immune system. Velcade's mechanism of action involves the inhibition of the 26S proteasome, leading to the accumulation of defective proteins and the induction of apoptosis in cancer cells.","oneSentence":"Thalidomide inhibits angiogenesis and immunomodulation, while Prednisone is a corticosteroid with anti-inflammatory effects, and Velcade (Bortezomib) is a proteasome inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:17.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Erythema nodosum leprosum"}]},"trialDetails":[{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00443235","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma More Than 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-03","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00320476","phase":"PHASE2","title":"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates","status":"COMPLETED","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-04","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00358020","phase":"PHASE2","title":"Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2004-11","conditions":"Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Thalidomide/Prednisone/Velcade","genericName":"Thalidomide/Prednisone/Velcade","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Velcade (Bortezomib) is a small molecule used in the treatment of multiple myeloma, often in combination with other medications such as Dexamethasone and Melphalan. In clinical trials, Velcade has been studied alongside Thalidomide and Prednisone, as well as other regimens, to evaluate its effectiveness in treating previously untreated multiple myeloma patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}